NCT02444819View on ClinicalTrials.gov

Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Non Small Cell Lung Cancer
Interventions
DRUG

HM61713

HM61713 will be administered to evaluate efficacy and safety of subjects.

Trial Locations (1)

Unknown

Seoul

Sponsors
All Listed Sponsors
lead

Hanmi Pharmaceutical Company Limited

INDUSTRY

NCT02444819 - Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy | Biotech Hunter | Biotech Hunter